Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 766.65 INR -1.48% Market Closed
Market Cap: 75B INR
Have any thoughts about
Shilpa Medicare Ltd?
Write Note

Shilpa Medicare Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shilpa Medicare Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Shilpa Medicare Ltd
NSE:SHILPAMED
Cost of Revenue
-â‚ą4.1B
CAGR 3-Years
-13%
CAGR 5-Years
-7%
CAGR 10-Years
-2%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cost of Revenue
-â‚ą88.2B
CAGR 3-Years
-8%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cost of Revenue
-â‚ą87.5B
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cost of Revenue
-â‚ą104.9B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cost of Revenue
-â‚ą27.5B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
M
Mankind Pharma Ltd
NSE:MANKIND
Cost of Revenue
-â‚ą34B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shilpa Medicare Ltd
Glance View

Market Cap
75B INR
Industry
Pharmaceuticals

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

SHILPAMED Intrinsic Value
1 131.61 INR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Shilpa Medicare Ltd's Cost of Revenue?
Cost of Revenue
-4.1B INR

Based on the financial report for Sep 30, 2024, Shilpa Medicare Ltd's Cost of Revenue amounts to -4.1B INR.

What is Shilpa Medicare Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-2%

Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Shilpa Medicare Ltd have been -13% over the past three years , -7% over the past five years , and -2% over the past ten years .

Back to Top